SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

Melanoma Clinical Trial

Official title:

Phase 2 Trial of SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03126461
• Other study ID #: STU 082016-058
• Status: Withdrawn
• Phase: Phase 2
• Start date: March 1, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: April 2018
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A one-arm, single center phase 2 trial of SAbR plus ipilimumab plus nivolumab in advanced metastatic melanoma patients

Description:

SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Histologic diagnosis of metastatic melanoma.

• Any number of prior systemic therapeutic regimens including chemotherapy, pathway inhibitors, biochemotherapy, investigational agents, and immunotherapies other than ipilimumab, nivolumab or other CTLA-4, PD-1 or PD-L1 inhibitors.

• Patients must have measurable disease in at least 2 non-radiated sites as defined by RECIST v1.1. All sites must be evaluated within 4 weeks prior to registration.

• Age = 18 years.

• Eligible for SABR to 1-5 sites of disease (Refer to 3.2.10)

• Performance status ECOG 0-2.

• Adequate organ and marrow function as defined below:

• leukocytes = 1,000/mcL

• absolute neutrophil count = 1,000/mcL

• platelets = 75,000/mcl

• total bilirubin < 2.5X institutional upper limit of normal or

• 3 in subjects with Gilbert's Syndrome

• AST(SGOT)/ALT(SPGT) = 4 X institutional upper limit of normal

• creatinine < 4X institutional upper limit of normal

• hemoglobin >7g/dL

• Ability to understand and the willingness to sign a written informed consent.

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of protocol treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Exclusion Criteria:

• No concomitant therapy with any of the following: IL2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; or other investigational therapies; all such therapies must have been discontinued >4weeks prior to registration.

• No infection with HIV and no known history of hepatitis B or hepatitis C virus indicating acute or chronic infection or active TB.

• Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than 2 years, with the exception of adequately treated (Surgery or radiation) and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or localized adenocarcinoma of the cervix.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Patients must not be pregnant or nursing.

• Patients are excluded if they have a history of prior treatment with ipilimumab, CTLA-4 inhibitor or agonist, nivolumab, PD-1 or PD-L1 inhibitor.

• Subjects who have had major surgery within 2 weeks prior to first dose of drug

• Subjects who have had radiation therapy within 2 weeks prior to first dose of drug

• Uncontrolled adrenal insufficiency or active chronic liver disease

• Any history of CNS metastases that is not adequately treated (surgery or radiation ) >14 days prior to registration.

• Any active known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

• Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalent are permitted (although not encouraged) in the absence of active autoimmune disease.

• Subjects with life expectancy < 6 months

• Subjects receiving any other investigational or standard antineoplastic agents.

Related Conditions & MeSH terms

• Melanoma
• Metastatic Melanoma

Intervention

Radiation:
• SAbR
For patients treated on the "GRID A" regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the "GRID B" regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose.

Drug:
• Ipilimumab
ipilimumab 3mg/kg IV q3wk x 4
• Nivolumab
nivolumab 1 mg/kg IV q3wk x 4

Locations

Country	Name	City	State
United States	University of Texas Southwestern Medical Center - Dallas	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of tumor size from baseline to follow up	treatment response rate-RR based on RECISTv1.1	at 12, 24, 36 weeks
Secondary	disease control rate	disease control rate defined as response plus stable disease based on RECISTv1.1	at 12, 24, 36 weeks
Secondary	Number of treatment-related adverse events	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	2 years
Secondary	programmed death ligand-1 (PD-L1) expression	compare tumor PD-L1 expression at 3 time points	baseline, cycle 1 Day 1, and week 15